이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IRLAB Therapeutics 과거 수익 실적

과거 기준 확인 0/6

IRLAB Therapeutics의 수입은 연평균 -12.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 8.4%의 비율로 증가했습니다. 매출은 연평균 26.8%의 비율로 증가해 왔습니다.

주요 정보

-13.5%

수익 성장률

-7.7%

EPS 성장률

Pharmaceuticals 산업 성장	30.5%
매출 성장률	19.3%
자기자본 수익률	-171.4%
순이익	-287.3%
다음 실적 업데이트	30 Oct 2024

최근 과거 실적 업데이트

Recent updates

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

수익 및 비용 분석

IRLAB Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:IRLAB A 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	42	-119	56
31 Mar 24	6	-157	43
31 Dec 23	6	-178	53
30 Sep 23	19	-176	44
30 Jun 23	36	-162	45
31 Mar 23	52	-144	54
31 Dec 22	61	-113	42
30 Sep 22	61	-103	39
30 Jun 22	240	42	37
31 Mar 22	217	43	35
31 Dec 21	208	52	31
30 Sep 21	196	55	27
30 Jun 21	0	-93	24
31 Mar 21	0	-93	24
31 Dec 20	0	-92	24
30 Sep 20	0	-99	23
30 Jun 20	0	-93	23
31 Mar 20	1	-98	11
31 Dec 19	0	-96	22
30 Sep 19	1	-88	21
30 Jun 19	1	-83	21
31 Mar 19	0	-76	20
31 Dec 18	0	-74	18
30 Sep 18	0	-68	20
30 Jun 18	0	-73	19
31 Mar 18	0	-60	27
31 Dec 17	0	-56	15
30 Sep 17	0	-58	13
30 Jun 17	0	-48	15
31 Mar 17	3	-44	14
31 Dec 16	3	-43	14
31 Dec 15	3	-12	10
31 Dec 14	3	3	5

양질의 수익: IRLAB A 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IRLAB A 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IRLAB A 은(는) 수익성이 없으며 지난 5년 동안 연간 12.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 IRLAB A 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IRLAB A 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 1.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IRLAB A 현재 수익성이 없기 때문에 마이너스 자본 수익률( -204.97% )을 갖습니다.

IRLAB Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Second quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Recent updates

IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757

IRLAB Therapeutics AB (publ) Granted Additional Patent for Its Drug Candidate Pirepemat Expanding the Patent Protection in the US

New minor risk - Profitability

IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee

Price target decreased by 7.1% to kr56.63

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

IRLAB Therapeutics AB (publ) Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Director recently bought kr260k worth of stock

IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Independent Vice Chairman of the Board recently bought kr330k worth of stock

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2021 Results on Apr 08, 2022

Independent Chairman recently bought kr74k worth of stock

Irlab Obtains Regulatory Approval to Conduct Phase IIb Study with Pirepemat

Independent Director recently bought kr112k worth of stock

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Chief Medical Officer recently sold kr1.8m worth of stock

Independent Director has left the company

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

IRLAB Announces First Patients in Europe Dosed in the clinical Phase IIb/III Study with Mesdopetam